NCT04844346

Brief Summary

Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, studies have suggested that these compounds also beneficially influence the immune system, e.g. increasing vaccine-specific antibody titers. BMI has previously been negatively associated to vaccination responses. If plant stanols indeed have beneficial effect on the immune system, people with overweight or obesity might benefit from consuming plant stanols prior to receiving the COVID-19 vaccination. The primary objective of this study is to demonstrate clinical benefits of consumption of plant stanols (delivered via products enriched with plant stanol esters) on the vaccination response to a COVID-19 vaccine in overweight or obese patients. The main study endpoint is vaccination response to a COVID-19 vaccine. Secondary endpoints include amongst others hematological, inflammatory and immunological parameters (e.g. hs-CRP, leukocyte differential count) and metabolic markers (e.g. blood lipid profiles, plasma glucose, serum insulin, HOMA-IR).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 14, 2021

Completed
8 days until next milestone

Study Start

First participant enrolled

April 22, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 11, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 11, 2022

Completed
Last Updated

March 2, 2022

Status Verified

February 1, 2022

Enrollment Period

9 months

First QC Date

April 13, 2021

Last Update Submit

February 11, 2022

Conditions

Keywords

OverweightObesityCOVID-19 vaccineImmune systemVaccination response

Outcome Measures

Primary Outcomes (1)

  • Vaccine specific antibody titers

    The response to the COVID-19 vaccine will be measured by quantifying specific antibody titers (vaccine specific IgG and IgM). These titers will be measured in blood samples collected weekly during the month after vaccination by suitable ELISAs.

    Change T=0 and T= 4 weeks

Secondary Outcomes (16)

  • Immune parameters (1)

    T=-1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination

  • Immune parameters (2)

    T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

  • Leukocyte count

    T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

  • Leukocyte differential count

    T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

  • Fasted metabolism (1)

    T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

  • +11 more secondary outcomes

Study Arms (2)

Plant stanol group

EXPERIMENTAL

This arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).

Dietary Supplement: Plant stanol mini drinksBiological: COVID-19 vaccine

Placebo group

PLACEBO COMPARATOR

This arm receives mini drinks without added plant stanols (delivered as plant stanol esters).

Dietary Supplement: Placebo mini drinksBiological: COVID-19 vaccine

Interventions

Plant stanol mini drinksDIETARY_SUPPLEMENT

Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).

Plant stanol group
Placebo mini drinksDIETARY_SUPPLEMENT

Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).

Placebo group

First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.

Placebo groupPlant stanol group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women
  • Aged 18 years or older
  • BMI between 27 and 35 kg/m2
  • Currently not using products containing plant sterols or stanols (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
  • Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
  • Willing to keep the intake of fish oil and vitamin supplements constant

You may not qualify if:

  • Already received COVID-19 vaccination
  • Already had a positive test for COVID-19 (this includes all types of tests, e.g. PCR tests or antibody tests)
  • Allergy to an ingredient of the mini drinks
  • Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
  • Pregnant women
  • Breastfeeding women
  • Excessive alcohol use (\>20 consumptions per week)
  • Regular use of soft or hard drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University Medical Center

Maastricht, Limburg, 6229ER, Netherlands

Location

Related Publications (1)

  • van Brakel L, Mensink RP, Lutjohann D, Plat J. Plant stanol consumption increases anti-COVID-19 antibody responses, independent of changes in serum cholesterol concentrations: a randomized controlled trial. Am J Clin Nutr. 2024 Apr;119(4):969-980. doi: 10.1016/j.ajcnut.2024.01.017. Epub 2024 Jan 24.

MeSH Terms

Conditions

OverweightObesity

Interventions

COVID-19 Vaccines

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Viral VaccinesVaccinesBiological ProductsComplex Mixtures

Study Officials

  • Jogchum Plat, PhD

    Maastricht University Medical Center

    PRINCIPAL INVESTIGATOR
  • Ronald P Mensink, PhD

    Maastricht University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 13, 2021

First Posted

April 14, 2021

Study Start

April 22, 2021

Primary Completion

January 11, 2022

Study Completion

January 11, 2022

Last Updated

March 2, 2022

Record last verified: 2022-02

Locations